Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Baxter Healthcare Corporation

ClinicalTrials.gov lists Baxter Healthcare Corporation as lead sponsor of 80 trials. It has 9 active development programs and 13 approved assets.

Manufacturer
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

26 0 1997 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 1 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 2 in 2026 and about 5 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

This page covers Baxter Healthcare Corporation: 80 lead-sponsored trials and 1 legal-entity registration.

Get the Baxter Healthcare Corporation report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (183)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Renal Insufficiency, Chronic 67
Kidney Failure, Chronic 58
Inflammation 25
Acute Kidney Injury 21
Hyperphagia 19

Trials by start year as sponsor or collaborator (29)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 1
2025 8
2024 10
2023 12
2022 8
2021 10
2020 8
2019 15
2018 17
2017 12

Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (9)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Sodium Glycerophosphate Injection Hyperphagia Phase 1 2
Sodium Phosphates Injection Hyperphagia Phase 1 1
DOXIL/CAELYX Multiple Myeloma Phase 1 1
DOXIL/CAELYX Ovarian Neoplasms Phase 1 1
Numeta G16%E Hyperphagia Phase 1 1

Approved assets (13)

Shown in this order: max phase first.

Approved assets
Drug Trials
INTRALIPID 2
Clinolipid 2
FLOSEAL Hemostatic Matrix + Standard of care 1
Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution 1
multiple electrolyte solution 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
55% hit target (n=22) 32% on time (n=22)

Journals published in (209)

Shown in this order: most published in first.

Journals published in
Journal Publications
Intensive care medicine 22
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 21
Critical care (London, England) 17
Clinical journal of the American Society of Nephrology : CJASN 15
Kidney international 14

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
1,187 242 2025-12-30

Organization relationships (8)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
PPD Development, LP Uses vendor 1
University Hospital, Bordeaux Co sponsors trial with 1
Elisabethinen Hospital Co sponsors trial with 1
Nexell Therapeutics Inc Co sponsors trial with 1
National University Health System, Singapore Co sponsors trial with 1

Latest dated events (1,515)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-04 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-12-30 Patent granted Granted US patents (PatentsView / USPTO)
2025-12-30 Patent granted Granted US patents (PatentsView / USPTO)
2025-12-30 Patent granted Granted US patents (PatentsView / USPTO)
2025-12-30 Patent granted Granted US patents (PatentsView / USPTO)

Biomarker capability evidence (246)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ALB Trial collaborator Named in trial inclusion criteria
ALB Trial collaborator Named in trial inclusion criteria
ALB Trial collaborator Named in trial inclusion criteria
AMH Trial collaborator Named in trial inclusion criteria
APOH Trial collaborator Primary endpoint in a Phase 3 trial

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.